Skip to content

Study · Randomized controlled trial · n = 1,104 · 2024

8 results

Plecanatide Improves Abdominal Bloating and Bowel Symptoms of Irritable Bowel Syndrome with Constipation.

Brenner DM, Sharma A, Rao SSC, Laitman AP, Heimanson Z, Allen C, Sayuk GS

Digestive diseases and sciences9 Apr 2024Cited by 13 (Europe PMC)

PMID38594429 (opens in a new tab)PMCIDPMC11098865 (opens in a new tab)DOI10.1007/s10620-024-08330-y (opens in a new tab)PepBankPUB-38594429
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In IBS-C with moderate-to-severe bloating, plecanatide reduced bloating severity versus placebo (least-squares mean change -1.7 versus -1.3; P = 0.002).

    In plain wordsIn IBS-C with moderate-to-severe bloating, plecanatide reduced bloating severity more than placebo.

    Peptide
    Plecanatide
    Outcome
    DecreaseBloating severity in moderate-to-severe subgroup
    Study

    n = 1,104

    Comparator
    Placebo
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    3 mg · 12 weeksAs given in this study (human).

    Measurements

    Bloating severity change
    −1.7 LSMC
    plecanatide 3 mg, moderate-to-severe bloating
    Bloating severity change
    −1.3 LSMC
    placebo, moderate-to-severe bloating
    P value
    0.002 P
    plecanatide versus placebo

    Source sentences

    Summary
    In the moderate-to-severe bloating subgroup, plecanatide significantly reduced bloating severity versus placebo (least-squares mean change [LSMC]: - 1.7 vs - 1.3; P = 0.002), reduced abdominal pain (- 1.7 vs - 1.3; P = 0.006), and increased CSBM frequency (1.4 vs 0.8; P < 0.0001).
    2 context sentences
    Summary · context
    Pooled phase 3 data (2 randomized, controlled IBS-C trials) from adults treated with plecanatide 3 mg or placebo for 12 weeks were analyzed.
    Summary · context
    Patients were stratified post-hoc by baseline bloating severity (11-point scale: mild [≤ 5] and moderate-to-severe [> 5]).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In IBS-C with moderate-to-severe bloating, plecanatide reduced abdominal pain versus placebo (-1.7 versus -1.3; P = 0.006).

    In plain wordsIn IBS-C with moderate-to-severe bloating, plecanatide reduced abdominal pain more than placebo.

    Peptide
    Plecanatide
    Outcome
    DecreaseAbdominal pain in moderate-to-severe subgroup
    Study

    n = 1,104

    Comparator
    Placebo
    Outcome group
    Pain · Gastrointestinal
    Studied dose
    3 mg · 12 weeksAs given in this study (human).

    Measurements

    Abdominal pain change
    −1.7 LSMC
    plecanatide 3 mg, moderate-to-severe bloating
    Abdominal pain change
    −1.3 LSMC
    placebo, moderate-to-severe bloating
    P value
    0.006 P
    plecanatide versus placebo

    Source sentences

    Summary
    In the moderate-to-severe bloating subgroup, plecanatide significantly reduced bloating severity versus placebo (least-squares mean change [LSMC]: - 1.7 vs - 1.3; P = 0.002), reduced abdominal pain (- 1.7 vs - 1.3; P = 0.006), and increased CSBM frequency (1.4 vs 0.8; P < 0.0001).
    2 context sentences
    Summary · context
    Pooled phase 3 data (2 randomized, controlled IBS-C trials) from adults treated with plecanatide 3 mg or placebo for 12 weeks were analyzed.
    Summary · context
    Patients were stratified post-hoc by baseline bloating severity (11-point scale: mild [≤ 5] and moderate-to-severe [> 5]).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In IBS-C with moderate-to-severe bloating, plecanatide increased CSBM frequency versus placebo (1.4 versus 0.8; P < 0.0001).

    In plain wordsIn IBS-C with moderate-to-severe bloating, plecanatide increased CSBM frequency more than placebo.

    Peptide
    Plecanatide
    Outcome
    IncreaseCSBM frequency in moderate-to-severe subgroup
    Study

    n = 1,104

    Comparator
    Placebo
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    3 mg · 12 weeksAs given in this study (human).

    Measurements

    CSBM frequency change
    1.4 LSMC
    plecanatide 3 mg, moderate-to-severe bloating
    CSBM frequency change
    0.8 LSMC
    placebo, moderate-to-severe bloating
    P value
    < 0.0001 P
    plecanatide versus placebo

    Source sentences

    Summary
    In the moderate-to-severe bloating subgroup, plecanatide significantly reduced bloating severity versus placebo (least-squares mean change [LSMC]: - 1.7 vs - 1.3; P = 0.002), reduced abdominal pain (- 1.7 vs - 1.3; P = 0.006), and increased CSBM frequency (1.4 vs 0.8; P < 0.0001).
    2 context sentences
    Summary · context
    Pooled phase 3 data (2 randomized, controlled IBS-C trials) from adults treated with plecanatide 3 mg or placebo for 12 weeks were analyzed.
    Summary · context
    Patients were stratified post-hoc by baseline bloating severity (11-point scale: mild [≤ 5] and moderate-to-severe [> 5]).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In IBS-C with moderate-to-severe bloating, pain and bloating composite response was 33.6% with plecanatide versus 26.8% with placebo (P = 0.02).

    In plain wordsIn IBS-C with moderate-to-severe bloating, plecanatide increased pain and bloating composite response versus placebo.

    Peptide
    Plecanatide
    Outcome
    IncreasePain and bloating composite response in moderate-to-severe subgroup
    Study

    n = 1,104

    Comparator
    Placebo
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    3 mg · 12 weeksAs given in this study (human).

    Measurements

    Pain and bloating composite response
    33.6%
    plecanatide 3 mg, moderate-to-severe bloating
    Pain and bloating composite response
    26.8%
    placebo, moderate-to-severe bloating
    P value
    0.02 P
    plecanatide versus placebo

    Source sentences

    Summary
    A significantly greater percentage of patients were abdominal pain and bloating composite responders with plecanatide versus placebo (moderate-to-severe bloating: 33.6% vs 26.8% [P = 0.02]; mild bloating: 38.4% vs 27.2% [P = 0.03]).
    2 context sentences
    Summary · context
    Pooled phase 3 data (2 randomized, controlled IBS-C trials) from adults treated with plecanatide 3 mg or placebo for 12 weeks were analyzed.
    Summary · context
    Patients were stratified post-hoc by baseline bloating severity (11-point scale: mild [≤ 5] and moderate-to-severe [> 5]).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In IBS-C with mild bloating, plecanatide reduced abdominal pain versus placebo (least-squares mean change -1.3 versus -1.0; P = 0.046).

    In plain wordsIn IBS-C with mild bloating, plecanatide reduced abdominal pain more than placebo.

    Peptide
    Plecanatide
    Outcome
    DecreaseAbdominal pain in mild bloating subgroup
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Pain · Gastrointestinal
    Studied dose
    3 mg · 12 weeksAs given in this study (human).

    Measurements

    Abdominal pain change
    −1.3 LSMC
    plecanatide 3 mg, mild bloating
    Abdominal pain change
    −1 LSMC
    placebo, mild bloating
    P value
    0.046 P
    plecanatide versus placebo

    Source sentences

    Summary
    In the mild bloating subgroup, significant improvements were observed with plecanatide versus placebo for abdominal pain (LSMC: - 1.3 vs - 1.0; P = 0.046) and CSBM frequency (2.0 vs 1.2; P = 0.003) but not bloating (- 0.9 vs - 0.8; P = 0.28).
    2 context sentences
    Summary · context
    Pooled phase 3 data (2 randomized, controlled IBS-C trials) from adults treated with plecanatide 3 mg or placebo for 12 weeks were analyzed.
    Summary · context
    Patients were stratified post-hoc by baseline bloating severity (11-point scale: mild [≤ 5] and moderate-to-severe [> 5]).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In IBS-C with mild bloating, plecanatide increased CSBM frequency versus placebo (2.0 versus 1.2; P = 0.003).

    In plain wordsIn IBS-C with mild bloating, plecanatide increased CSBM frequency more than placebo.

    Peptide
    Plecanatide
    Outcome
    IncreaseCSBM frequency in mild bloating subgroup
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    3 mg · 12 weeksAs given in this study (human).

    Measurements

    CSBM frequency change
    2 LSMC
    plecanatide 3 mg, mild bloating
    CSBM frequency change
    1.2 LSMC
    placebo, mild bloating
    P value
    0.003 P
    plecanatide versus placebo

    Source sentences

    Summary
    In the mild bloating subgroup, significant improvements were observed with plecanatide versus placebo for abdominal pain (LSMC: - 1.3 vs - 1.0; P = 0.046) and CSBM frequency (2.0 vs 1.2; P = 0.003) but not bloating (- 0.9 vs - 0.8; P = 0.28).
    2 context sentences
    Summary · context
    Pooled phase 3 data (2 randomized, controlled IBS-C trials) from adults treated with plecanatide 3 mg or placebo for 12 weeks were analyzed.
    Summary · context
    Patients were stratified post-hoc by baseline bloating severity (11-point scale: mild [≤ 5] and moderate-to-severe [> 5]).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In IBS-C with mild bloating, bloating change was -0.9 with plecanatide versus -0.8 with placebo, without significant difference (P = 0.28).

    In plain wordsIn IBS-C with mild bloating, plecanatide did not significantly change bloating severity versus placebo.

    Peptide
    Plecanatide
    Outcome
    No significant changeBloating severity in mild bloating subgroup
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    3 mg · 12 weeksAs given in this study (human).

    Measurements

    Bloating severity change
    −0.9 LSMC
    plecanatide 3 mg, mild bloating
    Bloating severity change
    −0.8 LSMC
    placebo, mild bloating
    P value
    0.28 P
    plecanatide versus placebo

    Source sentences

    Summary
    In the mild bloating subgroup, significant improvements were observed with plecanatide versus placebo for abdominal pain (LSMC: - 1.3 vs - 1.0; P = 0.046) and CSBM frequency (2.0 vs 1.2; P = 0.003) but not bloating (- 0.9 vs - 0.8; P = 0.28).
    2 context sentences
    Summary · context
    Pooled phase 3 data (2 randomized, controlled IBS-C trials) from adults treated with plecanatide 3 mg or placebo for 12 weeks were analyzed.
    Summary · context
    Patients were stratified post-hoc by baseline bloating severity (11-point scale: mild [≤ 5] and moderate-to-severe [> 5]).
  8. 08HumanRandomized controlled trialEfficacy outcome

    In IBS-C with mild bloating, pain and bloating composite response was 38.4% with plecanatide versus 27.2% with placebo (P = 0.03).

    In plain wordsIn IBS-C with mild bloating, plecanatide increased pain and bloating composite response versus placebo.

    Peptide
    Plecanatide
    Outcome
    IncreasePain and bloating composite response in mild subgroup
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    3 mg · 12 weeksAs given in this study (human).

    Measurements

    Pain and bloating composite response
    38.4%
    plecanatide 3 mg, mild bloating
    Pain and bloating composite response
    27.2%
    placebo, mild bloating
    P value
    0.03 P
    plecanatide versus placebo

    Source sentences

    Summary
    A significantly greater percentage of patients were abdominal pain and bloating composite responders with plecanatide versus placebo (moderate-to-severe bloating: 33.6% vs 26.8% [P = 0.02]; mild bloating: 38.4% vs 27.2% [P = 0.03]).
    2 context sentences
    Summary · context
    Pooled phase 3 data (2 randomized, controlled IBS-C trials) from adults treated with plecanatide 3 mg or placebo for 12 weeks were analyzed.
    Summary · context
    Patients were stratified post-hoc by baseline bloating severity (11-point scale: mild [≤ 5] and moderate-to-severe [> 5]).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.